Cancer Focus Fund
VC Fund
Shreveport, United States
Cancer Focus Fund is an investment firm that is dedicated to providing financial services to its clients. The company was founded by Ross Barrett.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 60%
- Fund size:
- $23M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Cancer Focus Fund invests in
Stages Cancer Focus Fund invests in
Countries Cancer Focus Fund invests in
Round sizes
Round size
- Series A
- $5.4M–$28M
- Venture - Series Unknown
- $4.5M–$47M
Investment Focus
Industry
- Biotechnology 5 (50%)
- Medical 3 (30%)
- Health Care 2 (20%)
- Life Science 2 (20%)
- Therapeutics 2 (20%)
Stage
- Venture - Series Unknown 4 (40%)
- Series A 3 (30%)
- Seed 1 (10%)
- Series B 1 (10%)
- Funding Round 1 (10%)
Country
- Israel 3 (30%)
- United States 2 (20%)
- Germany 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $18M / Series A / Feb 18, 2026 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $22M / Series B / Oct 15, 2025 | ||
| Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $5.1M / Venture - Series Unknown / Oct 23, 2024 | ||
| March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M / Series A / Oct 23, 2024 | ||
| Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes. Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors. It is founded in 2019 and is based in Martinsried, Bavaria. | $4.5M / Venture - Series Unknown / Mar 21, 2024 | ||
| March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $4.8M / Seed / Nov 09, 2023 | ||
| ImmunoGenesis develops science-driven immune therapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms. | $4.5M / Venture - Series Unknown / Jun 27, 2023 | ||
| Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies. | $5.4M / Series A / Mar 07, 2022 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M / Venture - Series Unknown / Jun 16, 2021 | ||
| See all 10 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Cancer Focus Fund invest in?
Cancer Focus Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Venture - Series Unknown and Series A stage. Most of the 10 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Cancer Focus Fund's check size?
Cancer Focus Fund typically joins rounds of $5.4M–$28M at Series A and $4.5M–$47M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cancer Focus Fund participates in.
When did Cancer Focus Fund last invest?
The most recent investment recorded for Cancer Focus Fund closed in Feb 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
